Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Kheng, Sim ^a   Muth, Sinoun ^a   Taylor, Walter R J ^a,b,c   Tops, Narann ^a   Kosal, Khem ^d   Sothea, Khon ^d   Souy, Phum ^e   Kim, Saorin ^f   Char, Chuor Meng ^a   Vanna, Chan ^g   Ly, Po ^a   Ringwald, Pascal ^h   Khieu, Virak ^a   Kerleguer, Alexandra ^f   Tor, Pety ^f   Baird, John K ^i,j   Bjorge, Steven ^a   Menard, Didier ^f   Christophel, Eva ^k  

^a National Center for Parasitology Entomology and Malaria Control ^*  (Cambodia)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^d Pailin Referral Hospital   (Cambodia)

^e Anlong Veng Referral Hospital   (Cambodia)

^f INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^g Pramoy Health Centre   (Cambodia)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^j UNIVERSITY OF OXFORD   (United Kingdom)

^k The World Health Organization Regional Office for the Western Pacific philippines   (Philippines)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DIHYDROARTEMISININ PLUS PIPERAQUINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN; PRIMAQUINE; ANTIMALARIAL AGENT;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BACKACHE; BLOOD TRANSFUSION; CAMBODIAN; CHILD; CHILL; CONJUNCTIVA DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; EPIGASTRIC PAIN; FEMALE; FEVER; GENOTYPE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEADACHE; HEARING IMPAIRMENT; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINURIA; HUMAN; JAUNDICE; MAJOR CLINICAL STUDY; MALE; METHEMOGLOBINEMIA; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PARALLEL DESIGN; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRESCHOOL CHILD; RELAPSE; SCHOOL CHILD; SORE THROAT; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; ANEMIA, HEMOLYTIC; CAMBODIA; CHEMICALLY INDUCED; COMORBIDITY; DRUG ADMINISTRATION; DRUG EFFECTS; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; MALARIA, VIVAX; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROCEDURES; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; ADULT; ANEMIA, HEMOLYTIC; ANTIMALARIALS; BLOOD TRANSFUSION; CAMBODIA; CHILD; COMORBIDITY; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; MALARIA, VIVAX; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PLASMODIUM VIVAX; PRIMAQUINE; SECONDARY PREVENTION;

EID: 84939810532     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0441-1     Document Type: Article

References (39)

1. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 2008;5, e128.
2. Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, et al. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med. 2008;5, e127.
3. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14:982-91.
4. White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011;10:297.
5. Collins WE, Jeffery GM. Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg. 1996;55:243-9.
6. Edgcomb JH, Arnold J, Yount Jr EH, Alving AS, Eichelberger L, Jeffery GM, et al. Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report. J Natl Malar Soc. 1950;9:285-92.
7. Krudsood S, Tangpukdee N, Wilairatana P, Phophak N, Baird JK, Brittenham GM, et al. High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am J Trop Med Hyg. 2008;78:736-40.
8. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013;369:1381-2.
9. Bolchoz LJ, Morrow JD, Jollow DJ, McMillan DC. Primaquine-induced hemolytic anemia: effect of 6-methoxy-8-hydroxylaminoquinoline on rat erythrocyte sulfhydryl status, membrane lipids, cytoskeletal proteins, and morphology. J Pharmacol Exp Ther. 2002;303:141-8.
10. Dern RJ, Beutler E, Alving AS. The hemolytic effect of primaquine. V. Primaquine sensitivity as a manifestation of a multiple drug sensitivity. J Lab Clin Med. 1955;45:30-9.
11. Beutler E, Duparc S. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 2007;77:779-89.
12. George JN, Sears DA, McCurdy PR, Conrad ME. Primaquine sensitivity in Caucasians: hemolytic reactions induced by primaquine in G-6-PD deficient subjects. J Lab Clin Med. 1967;70:80-93.
13. Monteiro WM, Franca GP, Melo GC, Queiroz AL, Brito M, Peixoto HM, et al. Clinical complications of G6PD deficiency in Latin American and Caribbean populations: systematic review and implications for malaria elimination programmes. Malar J. 2014;13:70.
14. Khoo KK. The treatment of malaria in glucose-6-phosphate dehydrogenase deficient patients in Sabah. Ann Trop Med Parasitol. 1981;75:591-5.
15. Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13:418.
16. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9, e1001339.
17. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report. Bull World Health Organ. 1960;22:621-31.
18. Clyde DF. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull World Health Organ. 1981;59:391-5.
19. Khim N, Benedet C, Kim S, Kheng S, Siv S, Leang R, et al. G6PD deficiency in Plasmodium falciparum and Plasmodium vivax malaria-infected Cambodian patients. Malar J. 2013;12:171.
20. Kim S, Nguon C, Guillard B, Duong S, Chy S, Sum S, et al. Performance of the CareStart G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening. PLoS One. 2011;6, e28357.
21. Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group. Bulletin of the World Health Organization. 1989;67:601.
22. Everett WD, Yoshida A, Pearlman E. Hemoglobin E and glucose-6-phosphate deficiency in the Khmer Air Force (Cambodia). Am J Trop Med Hyg. 1977;26:597-601.
23. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233-43.
24. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg. 2000;94:S1-S90.
25. http://rsc.tech-res.com/Document/safetyandpharmacovigilance/DAIDS-AE-Grading-Table-v1.0-DEC2004.pdf gradingtable.pdf.
26. Taylor WR, Widjaja H, Basri H, Tjitra E, Ohrt C, Taufik T, et al. Haemoglobin dynamics in Papuan and non-Papuan adults in northeast Papua, Indonesia, with acute, uncomplicated vivax or falciparum malaria. Malar J. 2013;12:209.
27. Akiyoshi T, Saito T, Murase S, Miyazaki M, Murayama N, Yamazaki H, et al. Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants. Drug Metab Dispos. 2011;39:724-8.
28. Sansone S, Rottensteiner J, Stocker J, Rosanelli C, Wiedermann CJ. Ciprofloxacin-induced acute haemolytic anaemia in a patient with glucose-6-phosphate dehydrogenase Mediterranean deficiency: a case report. Ann Hematol. 2010;89:935-7.
29. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383:1049-58.
30. Lacerda MV, Fragoso SC, Alecrim MG, Alexandre MA, Magalhaes BM, Siqueira AM, et al. Postmortem characterization of patients with clinical diagnosis of Plasmodium vivax malaria: to what extent does this parasite kill? Clin Infect Dis. 2012;55:e67-74.
31. Roca-Feltrer A, Khim N, Kim S, Chy S, Canier L, Kerleguer A, et al. Field trial evaluation of the performances of point-of-care tests for screening G6PD deficiency in Cambodia. PLoS One. 2014;9, e116143.
32. White NJ, Qiao LG, Qi G, Luzzatto L. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J. 2012;11:418.
33. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411-23.
34. Pannacciulli I, Tizianello A, Ajmar F, Salvidio E. The course of experimentally induced hemolytic anemia in a primaquine-sensitive Caucasian. A case study. Blood. 1965;25:92-5.
35. Pannacciulli I, Salvidio E, Tizianello A, Parravidino G. Hemolytic effects of standard single dosages of primaquine and chloroquine on G-6-PD-deficient Caucasians. J Lab Clin Med. 1969;74:653-61.
36. Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJ, et al. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan. PLoS One. 2008;3, e2861.
37. Charoenlarp P, Areekul S, Harinasuta T, Sirivorasarn P. The haemolytic effect of a single dose of 45 mg of primaquine in G-6-PD deficient Thais. J Med Assoc Thai. 1972;55:631-8.
38. Kondrashin A, Baranova AM, Ashley EA, Recht J, White NJ, Sergiev VP. Mass primaquine treatment to eliminate vivax malaria: lessons from the past. Malar J. 2014;13:51.
39. Leslie T, Briceno M, Mayan I, Mohammed N, Klinkenberg E, Sibley CH, et al. The impact of phenotypic and genotypic G6PD deficiency on risk of Plasmodium vivax infection: a case-control study amongst Afghan refugees in Pakistan. PLoS Med. 2010;7, e1000283.